Pharmaceutical manufacturers face unique challenges due to a highly regulated nature of the industry. Evolving healthcare landscape and supply chain disruptions due to COVID-19 pandemic are driving innovations changes across the entire value chain. The importance of speeding up activities in order to meet increasing demand globally became a key strategy. This awareness brought them into a retrospective exercise to identify key strategic areas of focus and as a natural consequence by adopting Industry 4.0 approach, pharma manufacturers can improve on key drivers of quality, productivity, speed and flexibility to achieve higher level of integration across the value chain and across the entire product lifecycle.
Industry 4.0 in a nutshell
Unique challenges for pharmaceutical manufacturers
Adopting Industry 4.0 in pharmaceutical environment
Success stories on adoption of I4.0 in pharmaceutical manufacturing
TÜV SÜD’s approach for Industry 4.0 transformation
Dr. Antonio Feraco
Vice President, TÜV SÜD Digital Service
Dr. Antonio Feraco is a Managing Consultant for Industry 4.0 and Vice President Digital Service at TÜV SÜD. He is responsible for supporting the process manufacturing sector in adopting technologies within the IIOT and Industry 4.0 space to enable end to end integration, improve HSE and optimise efficiency. With a PhD in Artificial Intelligence, a MSc in Industrial Engineer and a PMP®, Dr. Antonio ran successful projects in Oil and Gas, Mining and Pharma, and has been part of several international and large initiatives in EU and ASEAN, as a Digitisation and Industry 4.0 expert.
Dr. Pushkar Pendse
Principal Consultant, Industry 4.0, TÜV SÜD Digital Service
Dr. Pushkar Pendse is a Principal Consultant for Advanced Manufacturing at TÜV SÜD. He has close to 8 years of experience in life sciences from drug design, development to advanced manufacturing technologies. He has successfully led multiple projects on advanced analytics and process digital twins across the pharmaceutical product life cycle. Prior to joining the industry, he obtained his PhD in chemical engineering from University of Maryland College Park, USA with a specialisation in high-performance computing of biological systems.